Sonen Capital’s Pfizer PFE Stock Holding History

Sonen Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,914	Closed	-$200K	–	97
2023 Q1	$200K	Buy	4,914 +338	+7%	+$14.6K	0.34%	91
2022 Q4	$234K	Buy	+4,576	New	+$219K	0.38%	89
2022 Q3	–	Sell	-4,776	Closed	-$250K	–	106
2022 Q2	$250K	Buy	+4,776	New	+$243K	0.36%	91
2022 Q1	–	Sell	-4,517	Closed	-$267K	–	107
2021 Q4	$267K	Buy	+4,517	New	+$224K	0.26%	94

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sonen Capital's PFE Position: Q2 2023 in Review

Sonen Capital sold out of Pfizer (PFE) in Q2 2023, closing a stake of 4,914 shares — an estimated $200K sold.

Sonen Capital first reported a position in PFE in Q4 2021 and held it in 4 quarters. The position peaked at $267K in Q4 2021. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Sonen Capital reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Sonen Capital sold 4,914 Pfizer shares in Q2 2023, an estimated $200K.
Sonen Capital first reported a position in Pfizer in Q4 2021 and held it in 4 quarters.
Sonen Capital's Pfizer position peaked at $267K in Q4 2021.
3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Sonen Capital's 13F filing for Q2 2023, filed 7 Aug 2023.